Alejandro Sanchez
( out of 306 reviews )

Alejandro Sanchez, MD

Languages spoken: English, Spanish

Clinical Locations

Primary Location

Huntsman Cancer Institute - Cancer Hospital South

1950 Circle of Hope
Salt Lake City , UT 84112
801-585-0250
Get Directions

Huntsman Cancer Institute - Cancer Hospital South

Clinic 2B, Urology
1950 Circle of Hope
Salt Lake City , UT 84112
801-587-4381
Get Directions

  • Clinical Information

    Dr. Alejandro Sanchez is a native of Cali, Colombia. He is an Assistant Professor in the Division of Urology at the University of Utah School of Medicine and a Huntsman Cancer Institute investigator. Dr. Sanchez specializes in the surgical care of patients with urologic cancers using open, laparoscopic, robotic and endoscopic techniques. His practice at the Huntsman Cancer Institute primarily focuses on the multidisciplinary treatment of patients with prostate, bladder, kidney, testicular, adrenal, urethral and penile cancers.

    Academic Information

    Dr. Sanchez received his undergraduate degree from the University of Florida where he graduated Summa Cum Laude in Biochemistry. He earned his medical degree from Harvard Medical School and completed his urologic surgery training at Massachusetts General Hospital. Dr. Sanchez then completed a fellowship in urologic oncology at Memorial Sloan Kettering Cancer Center where he received a Young Investigator Award from the American Society of Urologic Oncology to evaluate the mechanisms underlying the association of sarcopenia (low skeletal muscle mass) and poor oncologic outcomes in patients with clear cell renal cell carcinoma. During his fellowship, Dr. Sanchez also received the Chairman’s Award for Excellence in Basic Science.

    As an Assistant Professor in the Division of Urology at the University of Utah School of Medicine and Huntsman Cancer Institute, Dr. Sanchez’s research efforts are primarily focused on clinical trial development and translational research.

    Specialties

    Patient Rating

    4.9 /5
    ( out of 306 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

    SUGAR HOUSE HEALTH CENTER

    Personable and skillful

    SUGAR HOUSE HEALTH CENTER

    Spends the time to listen to my concerns and provides compassionate and comforting care

    SUGAR HOUSE HEALTH CENTER

    I love this man !!! He treats me like a person not a number

    SUGAR HOUSE HEALTH CENTER

    `Very compassionate and caring. Good listener. Willing to take the time needed to make sure you understand the plan and to answer your questions.

    SUGAR HOUSE HEALTH CENTER

    He seems to be a very good Dr. I was impressed with him and his explanation of the treatment plan.

    SUGAR HOUSE HEALTH CENTER

    Excellent doctor. I'm very fortunate to have him as my doctor. Thank you Dr. Sanchez from the bottom of my heart.

    HUNTSMAN CANCER CENTER

    urine test cancelled the cystoscope. Not much time to get acquainted with Doctor. It was fine for its limited purpose

    SUGAR HOUSE HEALTH CENTER

    good

    SUGAR HOUSE HEALTH CENTER

    Dr Sanchez was professional, courteous and explained everything during the procedure. I would recommend him.

  • Clinical Information

    Dr. Alejandro Sanchez is a native of Cali, Colombia. He is an Assistant Professor in the Division of Urology at the University of Utah School of Medicine and a Huntsman Cancer Institute investigator. Dr. Sanchez specializes in the surgical care of patients with urologic cancers using open, laparoscopic, robotic and endoscopic techniques. His practice at the Huntsman Cancer Institute primarily focuses on the multidisciplinary treatment of patients with prostate, bladder, kidney, testicular, adrenal, urethral and penile cancers.

    Academic Information

    Dr. Sanchez received his undergraduate degree from the University of Florida where he graduated Summa Cum Laude in Biochemistry. He earned his medical degree from Harvard Medical School and completed his urologic surgery training at Massachusetts General Hospital. Dr. Sanchez then completed a fellowship in urologic oncology at Memorial Sloan Kettering Cancer Center where he received a Young Investigator Award from the American Society of Urologic Oncology to evaluate the mechanisms underlying the association of sarcopenia (low skeletal muscle mass) and poor oncologic outcomes in patients with clear cell renal cell carcinoma. During his fellowship, Dr. Sanchez also received the Chairman’s Award for Excellence in Basic Science.

    As an Assistant Professor in the Division of Urology at the University of Utah School of Medicine and Huntsman Cancer Institute, Dr. Sanchez’s research efforts are primarily focused on clinical trial development and translational research.

    Board Certification and Academic Information

    Academic Departments Surgery -Assistant Professor
    Academic Divisions Urology

    Education history

    Undergraduate Biochemistry and Microbiology - University of Florida B.S.
    Professional Medical Medicine - Harvard Medical School M.D.
    Internship General Surgery - Massachusetts General Hospital Intern
    Residency Urologic Surgery - Massachusetts General Hospital Resident
    Fellowship Urologic Oncology - Memorial Sloan Kettering Cancer Center Clinical Fellow

    Selected Publications

    Journal Article

    1. Gupta S, Argani P, Jungbluth AA, Chen YB, Tickoo SK, Fine SW, Gopalan A, Al-Ahmadie HA, Sirintrapun SJ, Sanchez A, Hakimi AA, Mcfarlane T, Salazar PA, Williamson SR, Skala SL, Mehra R, Hes O, Antonescu CR, Ladanyi M, Arcila ME, Reuter VE (2019). TFEB Expression Profiling in Renal Cell Carcinomas: Clinicopathologic Correlations. Am J Surg Pathol, 43(11), 1445-1461. (Read full publication)
    2. Graff RE, Cho E, Preston MA, Sanchez A, Mucci LA, Wilson KM (2018). Dietary Acrylamide Intake and Risk of Renal Cell Carcinoma in Two Large Prospective Cohorts. Cancer Epidemiol Biomarkers Prev, 27(8), 979-982. (Read full publication)
    3. Hanske J, Sanchez A, Schmid M, Meyer CP, Abdollah F, Feldman AS, Kibel AS, Sammon JD, Menon M, Eswara JR, Noldus J, Trinh QD (2015). A Comparison of 30-Day Perioperative Outcomes in Open Versus Minimally Invasive Nephroureterectomy for Upper Tract Urothelial Carcinoma: Analysis of 896 Patients from the American College of Surgeons-National Surgical Quality Improvement Program Database. J Endourol, 29(9), 1052-8. (Read full publication)
    4. Hanske J, Sanchez A, Schmid M, Meyer CP, Abdollah F, Roghmann F, Feldman AS, Kibel AS, Sammon JD, Noldus J, Trinh QD, Eswara JR (2015). Comparison of 30-day perioperative outcomes in adults undergoing open versus minimally invasive pyeloplasty for ureteropelvic junction obstruction: analysis of 593 patients in a prospective national database. World J Urol, 33(12), 2107-13. (Read full publication)
    5. Graff RE, Sanchez A, Tobias DK, Rodríguez D, Barrisford GW, Blute ML, Li Y, Sun Q, Preston MA, Wilson KM, Cho E (2018). The association between type 2 diabetes mellitus and incidence of renal cell carcinoma (RCC) and fatal RCC in two prospective cohorts. Diabetes Care.
    6. Graff RE, Sanchez A, Tobias DK, Rodríguez D, Barrisford GW, Blute ML, Li Y, Sun Q, Preston MA, Wilson KM, Cho E (2018). Type 2 Diabetes in Relation to the Risk of Renal Cell Carcinoma Among Men and Women in Two Large Prospective Cohort Studies. Diabetes Care, 41(7), 1432-1437. (Read full publication)
    7. Mendonca SJ, Sanchez A, Blum KA, Ghanaat M, Kashan MY, Benfante N, Russo P, Coleman JA, Crago AM, Hakimi A (2018). The association of renal cell carcinoma with gastrointestinal stromal tumors. Journal of surgical oncology, 117(8), 1716-1720. (Read full publication)
    8. Feldman AS, Meyer CP, Sanchez A, Krasnova A, Reznor G, Menon M, Kibel AS, Choueiri TK, Lipsitz SR, Sun M, Trinh Q (2017). Morbidity and Mortality of Locally Advanced Prostate Cancer: A Population Based Analysis Comparing Radical Prostatectomy versus External Beam Radiation. The Journal of urology, 198(5), 1061-1068. (Read full publication)
    9. Sanchez A, Wszolek MF, Niemierko A, Clayman RH, Drumm M, Rodríguez D, Feldman AS, Dahl DM, Heney NM, Shipley WU, Zietman AL, Efstathiou J (2018). Incidence, Clinicopathological Risk Factors, Management and Outcomes of Nonmuscle Invasive Recurrence after Complete Response to Trimodality Therapy for Muscle Invasive Bladder Cancer. The Journal of urology, 199(2), 407-415. (Read full publication)
    10. Kashan M, Ghanaat M, Hötker AM, Duzgol C, Sanchez A, DiNatale RG, Blum KA, Becerra MF, Manley BJ, Casuscelli J, Chiok M, Coleman JA, Russo P, Tickoo SK, Akin O, Hakimi A (2018). Cystic Renal Cell Carcinoma: A Report on Outcomes of Surgery and Active Surveillance in Patients Retrospectively Identified on Pretreatment Imaging. The Journal of urology, 200(2), 275-282. (Read full publication)
    11. Kreydin EI, Kim MM, Barrisford GW, Rodriguez D, Sanchez A, Santiago-Lastra Y, Ko D (2015). Urinary Lignans Are Associated With Decreased Incontinence in Postmenopausal Women. Urology, 86(4), 716-20. (Read full publication)
    12. Rodríguez D, Barrisford GW, Sanchez A, Preston MA, Kreydin EI, Olumi A (2014). Primary spermatic cord tumors: disease characteristics, prognostic factors, and treatment outcomes. Urologic oncology, 32(1), 52.e19-25. (Read full publication)
    13. Sanchez A, Rodriguez D, Allard CB, Bechis SK, Sullivan RJ, Boeke CE, Kuppermann D, Cheng JS, Barrisford GW, Preston MA, Feldman A (2016). Primary genitourinary melanoma: Epidemiology and disease-specific survival in a large population-based cohort. Urologic oncology, 34(4), 166.e7-14. (Read full publication)
    14. Mano R, Flynn J, Blum KA, Silagy AW, DiNatale RG, Marcon J, Wang A, Sanchez A, Coleman JA, Russo P, Ostrovnaya I, Hakimi A (2019). The predictive role of preoperative and postoperative neutrophil-lymphocyte ratio in sarcomatoid renal cell carcinoma. Urologic oncology, 37(12), 916-923. (Read full publication)
    15. Silagy AW, Flynn J, Mano R, Blum KA, Marcon J, DiNatale RG, Sanchez A, Carlo MI, Motzer RJ, Coleman JA, Russo P, Ostrovnaya I, Chen YB, Hakimi A (2019). Clinicopathologic features associated with survival after cytoreductive nephrectomy for nonclear cell renal cell carcinoma. Urologic oncology, 37(11), 811.e9-811.e16. (Read full publication)
    16. Sanchez A, Kissel S, Coletta A, Scott J, Furberg (2020). Impact of body size and body composition on bladder cancer outcomes: Risk stratification and opportunity for novel interventions. Urologic oncology, 38(9), 713-718. (Read full publication)
    17. Mano R, Duzgol C, Ganat M, Goldman DA, Blum KA, Silagy AW, Walasek A, Sanchez A, DiNatale RG, Marcon J, Kashan M, Becerra MF, Benfante N, Coleman JA, Kattan MW, Russo P, Akin O, Ostrovnaya I, Hakimi A (2020). Preoperative nomogram predicting 12-year probability of metastatic renal cancer - evaluation in a contemporary cohort. Urologic oncology, 38(11), 853.e1-853.e7. (Read full publication)
    18. Mano R, Duzgol C, Ganat M, Goldman DA, Blum KA, Silagy AW, Walasek A, Sanchez A, DiNatale RG, Marcon J, Kashan M, Becerra MF, Benfante NE, Coleman JA, Kattan MW, Russo P, Akin O, Ostrovnaya I, Hakimi A (2021). Somatic mutations as preoperative predictors of metastases in patients with localized clear cell renal cell carcinoma - An exploratory analysis. Urologic oncology, 39, 791.e17-791.e24. (Read full publication)
    19. Sanchez A, Furberg H, Kuo F, Vuong L, Ged Y, Patil S, Ostrovnaya I, Petruzella S, Reising A, Patel P, Mano R, Coleman J, Russo P, Liu CH, Dannenberg AJ, Chan TA, Motzer R, Voss MH, Hakimi A (2020). Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study. The Lancet. Oncology, 21(2), 283-293. (Read full publication)
    20. Sanchez A, Schoenfeld JD, Nguyen PL, Fiorentino M, Chowdhury D, Stampfer MJ, Sesso HD, Giovannucci E, Mucci LA, Shui I (2016). Common variation in BRCA1 may have a role in progression to lethal prostate cancer after radiation treatment. Prostate cancer and prostatic diseases, 19(2), 197-201. (Read full publication)
    21. Hutten RJ, Parsons MW, Weil CR, Tward JD, Lloyd S, Sanchez A, Lester-Coll N, Johnson S (2021). Temporal Trends and Predictors in Diagnosing Pathologic Node-Positive Prostate Cancer in Clinically Node-Negative Patients. Clinical genitourinary cancer, 19(6), e360-e366. (Read full publication)
    22. Sanchez A, Wszolek M (2015). Bladder cancer: Quality of life in patients with non-muscle-invasive bladder cancer. Nature reviews. Urology, 12(4), 186-8. (Read full publication)
    23. Hakimi AA, Voss MH, Kuo F, Sanchez A, Liu M, Nixon BG, Vuong L, Ostrovnaya I, Chen YB, Reuter V, Riaz N, Cheng Y, Patel P, Marker M, Reising A, Li MO, Chan TA, Motzer R (2019). Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear Cell Renal Cell Cancer: Data from a Randomized Phase III Trial. Cancer discovery, 9(4), 510-525. (Read full publication)
    24. DiNatale RG, Xie W, Becerra MF, Silagy AW, Attalla K, Sanchez A, Mano R, Marcon J, Blum KA, Benfante NE, Voss MH, Motzer RJ, Coleman J, Choueiri TK, Reznik E, Russo P, Heng DYC, Hakimi A (2019). The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive Nephrectomy. European urology oncology, (Read full publication)
    25. Hutten R, Khouri A, Parsons M, Tward A, Wilson T, Peterson J, Morrell G, Dechet C, O'Neil B, Schmidt B, Kokeny K, Lloyd S, Cannon D, Tward J, Sanchez A, Johnson (2022). The Clinical Significance of Maximum Tumor Diameter on MRI in Men Undergoing Radical Prostatectomy or Definitive Radiotherapy for Locoregional Prostate Cancer. Clinical genitourinary cancer, 20(6), e453-e459. (Read full publication)
    26. Graff RE, Wilson KM, Sanchez A, Chang SL, McDermott DF, Choueiri TK, Cho E, Signoretti S, Giovannucci EL, Preston M (2022). Obesity in Relation to Renal Cell Carcinoma Incidence and Survival in Three Prospective Studies. European urology, (Read full publication)
    27. Ged Y, Sanchez A, Patil S, Knezevic A, Stein E, Petruzella S, Weiss K, Duzgol C, Chaim J, Akin O, Mourtzakis M, Paris MT, Scott J, Kuo F, Kotecha R, Hakimi AA, Lee CH, Motzer RJ, Voss MH, Furberg (2022). Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade. Clinical cancer research, 28(23), 5180-5189. (Read full publication)
    28. Mano R, Hoeh B, DiNatale RG, Sanchez A, Benfante NE, Reznik E, Leitao MM, Shoushtari AN, Goh A, Donat SM, Herr HW, Bochner BH, Dalbagni G, Donahue T (2022). Urethral Melanoma - Clinical, Pathological and Molecular Characteristics. Bladder cancer (Amsterdam, Netherlands), 8(3), 291-301. (Read full publication)
    29. Hu S, Chang CP, Snyder J, Deshmukh V, Newman M, Date A, Galvao C, Haaland B, Porucznik CA, Gren LH, Sanchez A, Lloyd S, O'Neil B, Hashibe (2023). Mental health outcomes in a population-based cohort of patients with prostate cancer. Journal of the National Cancer Institute, 116(3), 445-454. (Read full publication)
    30. Michalek IM, Graff RE, Sanchez A, Choueiri TK, Cho E, Preston MA, Wilson K (2023). Evaluation of statin use and renal cell carcinoma risk identifies sex-specific associations with RCC subtypes. Acta oncologica (Stockholm, Sweden), 62(9), 988-993. (Read full publication)
    31. Hu S, Chang CP, Snyder J, Deshmukh V, Newman M, Date A, Galvao C, Porucznik CA, Gren LH, Sanchez A, Lloyd S, Haaland B, O'Neil B, Hashibe (2023). Comparing Active Surveillance and Watchful Waiting With Radical Treatment Using Machine Learning Models Among Patients With Prostate Cancer. JCO clinical cancer informatics, 7, e2300083. (Read full publication)
    32. Purdue MP, Dutta D, Machiela MJ, Gorman BR, Winter T, Okuhara D, Cleland S, Ferreiro-Iglesias A, Scheet P, Liu A, Wu C, Antwi SO, Larkin J, Zequi SC, Sun M, Hikino K, Hajiran A, Lawson KA, Cárcano F, Blanchet O, Shuch B, Nepple KG, Margue G, Sundi D, Diver WR, Folgueira MAAK, van Bokhoven A, Neffa F, Brown KM, Hofmann JN, Rhee J, Yeager M, Cole NR, Hicks BD, Manning MR, Hutchinson AA, Rothman N, Huang WY, Linehan WM, Lori A, Ferragu M, Zidane-Marinnes M, Serrano SV, Magnabosco WJ, BioBank Japan Project, Vilas A, Decia R, Carusso F, Graham LS, Anderson K, Bilen MA, Arciero C, Pellegrin I, Ricard S, FinnGen, Scelo G, Banks RE, Vasudev NS, Soomro N, Stewart GD, Adeyoju A, Bromage S, Hrouda D, Gibbons N, Patel P, Sullivan M, Protheroe A, Nugent FI, Fournier MJ, Zhang X, Martin LJ, Komisarenko M, Eisen T, Cunningham SA, Connolly DC, Uzzo RG, Zaridze D, Mukeria A, Holcatova I, Hornakova A, Foretova L, Janout V, Mates D, Jinga V, Rascu S, Mijuskovic M, Savic S, Milosavljevic S, Gaborieau V, Abedi-Ardekani B, McKay J, Johansson M, Phouthavongsy L, Hayman L, Li J, Lungu I, Bezerra SM, Souza AG, Sares CTG, Reis RB, Gallucci FP, Cordeiro MD, Pomerantz M, Lee GM, Freedman ML, Jeong A, Greenberg SE, Sanchez A, Thompson RH, Sharma V, Thiel DD, Ball CT, Abreu D, Lam ET, Nahas WC, Master VA, Patel AV, Bernhard JC, Freedman ND, Bigot P, Reis RM, Colli LM, Finelli A, Manley BJ, Terao C, Choueiri TK, Carraro DM, Houlston R, Eckel-Passow JE, Abbosh PH, Ganna A, Brennan P, Gu J, Chanock S (2024). Multi-ancestry genome-wide association study of kidney cancer identifies 63 susceptibility regions. Nature genetics, 56(5), 809-818. (Read full publication)
    33. Opurum PC, Decker ST, Stuart D, Peterlin AD, Paula VL, Siripoksup P, Drummond MJ, Sanchez A, Ramkumar N, Funai (2025). Combined sedentarism and high-fat diet induce early signs of kidney injury in C57BL/6J mice. American journal of physiology. Renal physiology, (Read full publication)
    34. Tward J, Lloyd S, Johnson S, Dechet C, Nei BO, Maughan B, Swami U, Gupta S, Sanchez A, Kokeny K, Agarwal (2025). A Phase 2 Trial of Radium(223) and Stereotactic Ablative Radiation Therapy in Hormone-Naïve Men with Oligometastatic Prostate Cancer to Bone: The RadSABR Study. International journal of radiation oncology, biology, physics, (Read full publication)
    35. Galarza Fortuna GM, Grass D, Maughan BL, Jain RK, Dechet C, Beck J, Schuetz E, Sanchez A, O'Neil B, Poch M, Li R, Lloyd S, Tward J, Phunrab T, Hawks JL, Swami U, Boucher KM, Agarwal N, Gupta (2025). Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT). Journal for immunotherapy of cancer, 13(3), (Read full publication)
    36. Kohlmann W, Nix DA, Pauley K, Greenberg S, Atkinson A, Boucher KM, Kolesar J, Singer EA, Edge SB, Churchman ML, Graham L, Salhia B, Sanchez A, Zakharia Y, Nepple KG, Schneider BP, Byrne L, Jain RK, Chahoud J, Feng BJ, Gupta (2024). Inherited Germline Variants in Urinary Tract Cancer: A Multicenter Whole-Exome Sequencing Analysis and Correlation With Clinical Features and Tumor Genomics. JCO precision oncology, 8, e2300697. (Read full publication)
    37. Dindinger-Hill K, Hu S, Hickman A, Choudry M, Vehawn J, Snyder J, Deshmukh V, Newman M, Date A, Galvao C, Kohli M, O'Neil B, Schmidt B, Dechet C, Hashibe M, Sanchez (2024). Association of Baseline Pre-Diagnosis and Post-Diagnosis Obesity and Weight Change with Cardiovascular Risk and Survival Among Nonmetastatic Prostate Cancer Survivors. Clinical genitourinary cancer, 22(3), 102057. (Read full publication)
    38. Eule CJ, Hu J, Hedges D, Jani A, Pshak T, Manley BJ, Sanchez A, Dreicer R, Myint ZW, Zakharia Y, Lam E (2024). Clinical and Genomic Features of Patients with Renal Cell Carcinoma and Advanced Chronic Kidney Disease: Analysis of a Multi-Institutional Database. Cancers, 16(10), (Read full publication)
    39. Bradshaw PT, Olsson LT, Sanchez A, Knezevic A, Akin O, Scott JM, Hakimi AA, Russo P, Caan BJ, Mourtzakis M, Furberg (2024). Radiodensities of Skeletal Muscle and Visceral Adipose Tissues Are Prognostic Factors in Clear-Cell Renal Cell Carcinoma. Cancer epidemiology, biomarkers & prevention, 33(10), 1375-1382. (Read full publication)
    40. Furberg H, Bradshaw PT, Knezevic A, Olsson L, Petruzella S, Stein E, Paris M, Scott J, Akin O, Hakimi AA, Russo P, Sanchez A, Caan B, Mourtzakis (2024). Skeletal muscle and visceral adipose radiodensities are pre-surgical, non-invasive markers of aggressive kidney cancer. Journal of cachexia, sarcopenia and muscle, 15(2), 726-734. (Read full publication)
    41. Blum KA, Silagy AW, Knezevic A, Weng S, Wang A, Mano R, Marcon J, DiNatale RG, Sanchez A, Tickoo S, Gupta S, Motzer R, Haas NB, Kim SE, Uzzo RG, Coleman JA, Hakimi AA, Russo (2024). Localised non-metastatic sarcomatoid renal cell carcinoma: a 31-year externally verified study. BJU international, 133(2), 169-178. (Read full publication)
    42. Nixon BG, Kuo F, Ji L, Liu M, Capistrano K, Do M, Franklin RA, Wu X, Kansler ER, Srivastava RM, Purohit TA, Sanchez A, Vuong L, Krishna C, Wang X, Morse Iii HC, Hsieh JJ, Chan TA, Murphy KM, Moon JJ, Hakimi AA, Li M (2022). Tumor-associated macrophages expressing the transcription factor IRF8 promote T cell exhaustion in cancer. Immunity, 55(11), 2044-2058.e5. (Read full publication)
    43. Marcon J, DiNatale RG, Sanchez A, Kotecha RR, Gupta S, Kuo F, Makarov V, Sandhu A, Mano R, Silagy AW, Blum KA, Nassau DE, Benfante NE, Ortiz MV, Carlo MI, Chan TA, Motzer RJ, Voss MH, Coleman J, Russo P, Reuter V, Hakimi AA, Reznik (2020). Comprehensive Genomic Analysis of Translocation Renal Cell Carcinoma Reveals Copy-Number Variations as Drivers of Disease Progression. Clinical cancer research, 26(14), 3629-3640. (Read full publication)
    44. Makarov DV, Thomas JK, Ciprut S, Rivera AJ, Sherman SE, Braithwaite RS, Best SL, Blakely S, D'Agostino LA, Dahm P, Dash A, Leapman MS, Leppert JT, Sanchez A, Shelton JB, Tessier CD, Tenner CT, Gold HT, Shedlin MG, Zeliadt S (2025). Prostate Cancer Imaging Stewardship: a multimodal, physician-centered intervention for guideline-concordant imaging. Journal of the National Cancer Institute, 117(11), 2308-2316. (Read full publication)
    45. Feng BJ, Kohlmann W, Nix DA, Atkinson A, Boucher KM, Carroll C, Stubben CJ, Kolesar J, Singer EA, Riedlinger G, Edge S, Sahu KK, Churchman M, Graham L, Salhia B, Sanchez A, Zakharia Y, Schneider BP, Jain R, Byrne L, Moskaluk CA, Nepple K, Shabsigh A, Chahoud J, Cairns BR, Gupta (2025). Germline whole-exome sequencing reveals FOXP3-related gene variants conferring urinary cancer susceptibility and associated with immune escape. Journal for immunotherapy of cancer, 13(9), (Read full publication)
    46. Olsson LT, Sanchez A, Mourtzakis M, Hakimi AA, Russo P, Jaimes EA, Bradshaw PT, Furberg (2025). Body Composition May Be a Novel Presurgical Risk Factor for Acute Kidney Injury among Clear Cell Renal Cell Cancer Patients Undergoing Radical Nephrectomy. Journal of kidney cancer and VHL, 12(4), 19-29. (Read full publication)

    Review

    1. Sanchez A, Feldman AS, Hakimi A (2018). Current Management of Small Renal Masses, Including Patient Selection, Renal Tumor Biopsy, Active Surveillance, and Thermal Ablation. Journal of clinical oncology, 36(36), 3591-3600. (Read full publication)
    2. DiNatale RG, Sanchez A, Hakimi AA, Reznik (2019). Metabolomics informs common patterns of molecular dysfunction across histologies of renal cell carcinoma. Urologic oncology, (Read full publication)
    3. Silagy AW, Sanchez A, Manley BJ, Bensalah K, Bex A, Karam JA, Ljungberg B, Shuch B, Hakimi A (2019). Harnessing the Genomic Landscape of the Small Renal Mass to Guide Clinical Management. European urology focus, 5(6), 949-957. (Read full publication)

    Book Chapter

    1. Kaufman CS, Sanchez A, Ayyagari (2021). Image-Guided Targeted Prostate Biopsies. Techniques in vascular and interventional radiology, 24(4), 100777. (Read full publication)

    Case Report

    1. Vehawn J, Choudry M, Mahlow J, Agarwal J, Dechet C, Sanchez (2022). Case of testicular nonseminomatous germ cell tumor cancer soft tissue seeding after inguinal orchiectomy. Urology case reports, 43, 102120. (Read full publication)
    2. Chapman L, Keihani S, Sanchez (2024). Intraperitoneal Bleeding After Ultrasound-Guided Transperineal Prostate Biopsy. Case reports in urology, 2024, 8819291. (Read full publication)
    3. Sung D, Sanchez A, Tward J (2023). Successful Salvage Brachytherapy after Infusion of Gold AuroShell Nanoshells for Localized Prostate Cancer in a Human Patient. Advances in radiation oncology, 8(4), 101202. (Read full publication)
    4. Marshall MB, Dindinger-Hill K, Swami U, Lyden S, Sanchez (2023). Intraperitoneal seeding of a testicular mixed germ cell tumor following spontaneous intraperitoneal mass rupture with associated anti-NMDA paraneoplastic encephalitis. Urology case reports, 48, 102427. (Read full publication)

    Editorial

    1. Kissel S, Sanchez (2020). Receipt of Survivorship Care Plans and Self-Reported Health Status Among Patients with Genitourinary Malignancy. The Journal of urology, 204(3), 569. (Read full publication)
    2. Sanchez A, Eisner B (2013). Visceral Fat is Correlated With Prolonged Operative Time in Laparoendoscopic Single-Site Adrenalectomy and Laparoscopic Adrenalectomy. Urology, 82(6), 1318. (Read full publication)
    3. Sanchez A, Agarwal (2021). Quantifying the Costs of Care Among Patients With High-Risk Non-Muscle-Invasive Bladder Cancer Treated in the Veterans Health Administration. JAMA network open, 4(3), e213816. (Read full publication)

    Letter

    1. Sanchez A, Furberg H (2020). Understanding the obesity paradox in cancer: looking to body composition and tumor-specific biology to understand this complex association [Letter to the editor]. Am J Clin Nutr. (Read full publication)
    2. Sanchez A, Furberg (2020). Obesity Paradox in Patients With Non-Small Cell Lung Cancer Treated With Immunotherapy. JAMA oncology, 6(6), 940-941. (Read full publication)
    3. Mahlow J, Sanchez A, Barry M, Sirohi (2022). Composite pheochromocytoma/paraganglioma-ganglioneuroma with a germline SDHC mutation: a first of its kind case report. Histopathology, 81(5), 682-685. (Read full publication)

    Abstract

    1. Sanchez A, Kuo F, Petruzella S, Akin O, Paris M, Russo P, Chan TA, Mourtzakis M, Hakimi A, Furberg (2019). Mechanisms underlying the association between sarcopenia and poor oncologic outcomes in clear cell renal cell carcinoma. Journal of clinical oncology, 37(7_suppl), 662.
    2. Voss MH, Kuo F, Sanchez A, Ostrovnaya I, Cheng Y, Patel P, Marker M, Reising A, Chan TA, Motzer RJ, Hakimi A (2018). Characterizing tumor immune microenvironment (TME) and outcomes of 409 patients (pts) treated on COMPARZ: Distinct clusters emphasize immune infiltration and angiogenesis. Journal of clinical oncology, 36(15_suppl), 4515.

    Other

    1. Moses KA, Sprenkle PC, Bahler C, Box G, Carlsson SV, Catalona WJ, Dahl DM, Dall'Era M, Davis JW, Drake BF, Epstein JI, Etzioni RB, Farrington TA, Garraway IP, Jarrard D, Kauffman E, Kaye D, Kibel AS, LaGrange CA, Maroni P, Ponsky L, Reys B, Salami SS, Sanchez A, Seibert TM, Shaneyfelt TM, Smaldone MC, Sonn G, Tyson MD, Vapiwala N, Wake R, Washington S, Yu A, Yuh B, Berardi RA, Freedman-Cass D (2023). NCCN Guidelines® Insights: Prostate Cancer Early Detection, Version 1.2023. Journal of the National Comprehensive Cancer Network, 21(3), 236-246. (Read full publication)

  • News & Podcasts

    Huntsman Cancer Institute News

Schedule Online